Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.
González-Sánchez E, Muñoz-Callejas A, Gómez-Román J, San Antonio E, Marengo A, Tsapis N, Bohne-Japiassu K, González-Tajuelo R, Pereda S, García-Pérez J, et al. Br J Pharmacol. 2022 Sep; 179(18):4534-4548. Epub 2022 Jul 13.